winner of the 1996 Nobel Prize in Physiology or Medicine, Peter C. Doherty, highlighted the effectiveness of the Sputnik V vaccine against coronavirus. He also said that possible dose changes before new variants of the virus will not cause difficulties for its creators.
In statements to the Russian news agency TASS, Doherty highlighted the use of viral vectors in the manufacture of the drug developed by the Gamaleya Center.
“The effectiveness of the Sputnik V vaccine – over 90% – looks very good and also Russia has a long history of developing good vaccines. The strategy of using two adenovirus vectors makes sense and is, as I understand it, used in Sputnik. Of course, if the virus changes significantly as a result of the mutation, vaccine manufacturers will have to correct “the drug a little, but it will not be difficult,” the specialist commented.
Lancet publishes results of Russian vaccine: its effectiveness is 91.6%
According to an interim analysis of phase 3 of the clinical trials, which was published on Tuesday, February 2, in the medical journal Lancet, the Russian coronavirus Sputnik V vaccine has an overall efficacy of 91.6%.
The publication points out that these studies involved 21,977 adults, who were randomly assigned to the vaccine group (16,501 people) and the placebo group (5,746) between 7 September and 24 November 2020.
In total, 19,866 volunteers received the two doses required for immunization and, among them, only 78 cases of Covid-19 were confirmed.